
ãµã«ç ã¢ããããŒãïŒãããŒãã»ãããŒã³å士ã«ããã°ãé倧ãªé²å±ããã£ããšã®ããšã§ã
1é±éåãRobert Maloneå士ã¯ãç¿çã«ã€ããŠãããã£ãŠããããšããè¿°ã¹ãèšäºãæžããŸããã仿¥ãåœŒã¯æŽæ°ãçºè¡šããã
ãããæžããŠããèªåãã»ãšãã©ä¿¡ããããªããããã®ãããã¯ã«é¢ããç§ã®æåã®Substackã®èšäºä»¥æ¥ãæã ã¯ããã€ãªããé¢é£ã®ç¿çãŠã€ã«ã¹ã®æŸåºãã¢ãã«ãšããã€ãã³ã201ã¹ã¿ã€ã«ã®ãŠã©ãŒã²ãŒã æŒç¿ãæããã«ããããäžååãªãã€ãªã»ãŒããã£ãšãã€ãªã»ãã¥ãªãã£ã®èŠå®ãšåŒ±ãç£èŠãæã€å®éšå®€ã§äœãããç åèã䜿ã£ãããæ»æã«ãããããšåœŒã¯ä»æ¥æžããŠããã
é²éªšãªææãã«ãã¯ããæ¢ããããªãã®ãïŒæ¯é ãããã¡ãã£ã¢ã¯æ¥ããããšããªãã

ãããããã«ãã»ã¬ãŒã¬ã³ããŸã çããŠããããããŸããããšãã声ãèãããŠãããã ããŸããå ¬è¡è¡çã«é¢é£ããææãã«ãããã¡ãã£ã¢ãæããŠäžæã«æµããããäŸãã°ã2022幎5æ20æ¥ã®ãžã§ã€ã¯ã»ã¿ãããŒã®CNNæŸéçªçµãThe Leadãããã®ç»åïŒäžïŒã¯ãç§ã«ã¯ãµã«çã§ã¯ãªã倩ç¶çã®çäŸã«èŠãããããäžã€ã®äŸã¯ã以äžã®èªæãªãã¢ã®ç»åã«é¢ãããã®ã§ããã

ãã¡ããããã«ïŒã¡ãªã³ãã»ã²ã€ããåºè³ããGAVIã®ããã¹ãããæ»äº¡ç10ïŒ ãšããæ¥µããŠé²éªšãªãã®ã§ãããã¯ãµã«çãšææãã«ãã«é¢ãã以åã®Substackèšäºã§åãäžããŸããã
ãããæžããŠããèªåãã»ãšãã©ä¿¡ããããªããããã®è©±é¡ã«é¢ããç§ã®æåã®Substackèšäºä»¥æ¥ãæã ã¯ãããã€ãªã»ãŒããã£ãšãã€ãªã»ãã¥ãªãã£ã®èŠå®ãäžååã§ç£èŠã匱ãå®éšå®€ã§æäœãããç åäœã䜿ã£ãããæ»æã«ããã人工ç¿çãŠã€ã«ã¹ã®ãã€ãªããé¢é£ã®æŸåºãã¢ãã«ãšããã€ãã³ã201ã¹ã¿ã€ã«ã®ãŠã©ãŒã²ãŒã æŒç¿ãæããã«ããŠãããé©ãã¹ãïŒå¶ç¶ã®ïŒïŒå èŠæ§ã§ã2021幎3æã®ãåäžæŒç¿ãïŒã³ããã屿©ãã1幎3ã¶æïŒã¯ã2022幎5æ15æ¥ã«éå§ããããµã«çãã€ãªãããã¢ãã«ã«ããŠãããCNNãšãžã§ã€ã¯ã»ã¿ãããŒã®ææãã«ãäœåã®æ¥ä»ã2022幎5æ20æ¥ã«æ³šç®ããŠãã ããããã®ãæŒç¿ãã®ããŒã¹ãšãªã£ãã·ããªãªã§å±éãããã¢ããªã³ã°ã¯ã2023幎12æ1æ¥ãŸã§ã«32åäººã®ææè ãš2å7100äžäººã®æ»è ãäºæž¬ãããã®ã§ããããã¡ããããã®ã·ããªãªãè£ä»ããããã«äœ¿ããããããªåçŽåãããå ¬è¡è¡çã¢ãã«ã®äºæž¬ç²ŸåºŠã¯ãçµ¶å¯Ÿã«æãããããšãç¹°ãè¿ã蚌æãããŠããããã®çš®ã®ã¢ãã«ã¯ãCNNãMSNBCãNYTãã¯ã·ã³ãã³ãã¹ããªã©ã®æææ¿æ²»ã®å£²äººã«ãã£ãŠããŸãã«ãé »ç¹ã«æŠåšãšããŠäœ¿ãããéç§åŠçæšæž¬ãšããŠãŽãç®±ã«è¿œãããããããç¶ç¶çã«ãŽãç®±è¡ãã«ãªãã¹ãã ãä»ãŸã§ã«ãç§ãã¡ã¯çãUSGãšWEFã«æ¯é ããããã€ãã®ã¡ãã£ã¢é¢ä¿è ãç¥ã£ãŠããã

ã€ã¿ãªã¢äººã®å£ç
äœããããå¶ç¶ã§ã¯ãªãã®ã§ãã
å¶ç¶ã«èµ·ããããšã¯äœããªãã
çŸåšããã£ãŠããããã«ããã®ã¢ãã«åãããæ¥ä»ã®é©ãã¹ãå èŠæ§ã¯ãã¡ããã©çµäºããã°ããã®éèŠãªWHOäŒè°ã®çŽåã«ãã£ããWHOã«åœå®¶æ²æ³ããã€ãã¹ããåäŸã®ãªãæš©éãäžããåœéä¿å¥èŠåïŒIHRïŒã®ä¿®æ£ïŒç±³åœä¿å¥çã2022幎1æ23æ¥ã«ææ¡ïŒã掻çºã«æ€èšãããããåœå®¶äž»æš©ã®äŸµå®³ã«é¢ããã¢ããªã«è«žåœã®æžå¿µããäž»ã«å°æ¥ã®äŒè°ïŒïœ2022幎11æïŒã«å éããããããã®ãæŒç¿ãã®ç®çã¯ãç±³åœHHSãæåºããIHRã®ä¿®æ£æ¡ã§æç€ºãããç®çããããã¯ãšé©ãã»ã©ããäžèŽããŠããïŒ
ç¹å®ã®æè¡ã®é²æ©ã«äŒŽã£ãŠçããå¯èœæ§ã®ããæ°ããªçç©åŠçãªã¹ã¯ãäœæžããããšãç®çãšãããæ°ããªã°ããŒãã«ãã€ãªã»ãã¥ãªãã£æ©é¢ãèšç«ããããšããã®äœ¿åœã¯ããã匷åºãªäžççãã€ãªã»ãã¥ãªãã£èŠç¯ãæšé²ãããããç¶æããããã®ææ®µãšã€ã³ã»ã³ãã£ããéçºããããšã«ãããçç©ç§åŠãšãã€ãªãã¯ãããžãŒã®äºæ ãäžæ³šæã«ãã誀çšããããã¯æ æã®ä¹±çšã«ããç Žæ» çãªçµæã®ãªã¹ã¯ãäœæžããããšã§ããã
åå äžæã®é倧ãªçç©åŠçäºè±¡ã調æ»ããããã®æ°ããªå ±åè©äŸ¡ã¡ã«ããºã ã®èšç«ã®å¯èœæ§ãæ€èšããããšããã®æ°ã¡ã«ããºã ã¯ãäžçä¿å¥æ©é¢ïŒWHOïŒã®ææççºç調æ»èœåãšãæå³çãªçç©å µåšäœ¿çšã®çãã調æ»ããåœé£äºåç·é·ã®ã¡ã«ããºã ãªã©ãæ¢åã®ã¡ã«ããºã ã®ãç¶ãç®ãã§æ©èœãããã³ãããã¯çºçæºã®èª¿æ»ã«å¯Ÿããåœé£ã·ã¹ãã ã®èœåã匷åããã
äžççãªå¥åº·å®å šä¿éãšãã³ãããã¯å¯Ÿçã®ããã®è§Šåªçãªå€åœéè³é調éã¡ã«ããºã ã®ç¢ºç«ãæå±ããããšããã®ç®çã¯ãè³æºãæãå¿ èŠãšããåœã ã«ãããŠãæç¶å¯èœãªãã€ãªã»ãã¥ãªãã£ãšãã³ãããã¯å¯Ÿçã®èœåæ§ç¯ãå éãããããšã§ããã

ã§ã¯ããŸãæ°ã㪠"ãã©ã³ããã㯠"ã®äºäŸãçãŸããã®ã§ããããïŒç§ãèšããããšã¯ããã äžã€ã
"ãããç§ãã¡ã¯äœãšè€éãªç¶²ãç¹ã£ãŠããã®ã ãããæåã«éšãç·Žç¿ããããšãã«"
ãŠã©ã«ã¿ãŒã»ã¹ã³ããèãããŒããªã³ãã
ãšãããããã£ãšé©åãªèšèãããã®ã§ã¯ãªãã§ããããã
ã€ã¿ãªã¢ã«ã¯ãäžåºŠã§ãç§ã欺ããè ã¯åœŒã®è²¬ä»»ãäºåºŠç®ã¯ç§ã®è²¬ä»»ããšãã諺ãããã
ã¢ã³ãœããŒã»ãŠã§ã«ãã³ããžã§ãŒã ãºçã®å®®å»·ãšæ§æ Œã(1651幎)
å ã«æžããããµã«çãçå®å¯Ÿææãã«ãããšé¡ãããµãã¹ã¿ãã¯ã®äžã§ãç§ã¯æ¬¡ã®ãããªæ³šææžãã§ãšãã»ã€ãçµãã§ããã
é²åãæå³çãªéºäŒåæäœã«ãã£ãŠäœããã®éºäŒåå€åããªãéãããã®ç æ°ã¯é倧ãªçç©åŠçè åšã§ã¯ãªããéå»ã«è åšã®é«ãç åäœãšã¿ãªãããããšã¯äžåºŠããªãã

ãã®ææçã¯ãã«ããªã¢è«žå³¶ïŒãçŽ8äžäººãåå¡ããã«ããªã¢è«žå³¶ã®ã²ã€ã»ãã©ã€ãã»ã€ãã³ããïŒãšããããªãŒãã®ãµãŠãããšããããšãŒãããã®äºã€ã®å€§ããªãã³ã¹ã»ããŒãã£ãŒã»ã€ãã³ãïŒãRavesãïŒã«ç«¯ãçºããŠããããã§ãããã«ããªã¢è«žå³¶ã®ã€ãã³ãã¯ããã¹ãããã¹ã²ã€ãã©ã€ããã®20åšå¹Žèšå¿µã§ã5æ5æ¥ãã5æ15æ¥ãŸã§è¡ãããïŒä»¥åã¢ãã«åãããç¿çã®çç©å µåšãæŸåºãããæ£ç¢ºãªæ¥ïŒãäž»å¬è ã¯ã10äžäººä»¥äžã®åå è ã«ããå€§èŠæš¡ãªãã¬ãŒããããŒãããªãããããŒã«ããŒãã£ãŒãªã©ãçãã ãããã®å 容ïŒããšäºæ³ããŠãããã€ãŸããæå³çã§ãããäžæ³šæã§ããããµã«çã®è¶ æ¡æ£ã€ãã³ãã«ã¯çµ¶å¥œã®æ©äŒãªã®ã§ããããããHIVã«ææãããšã€ãºã®æŽå²ã念é ã«çœ®ããªãããç§»åæ§ã®é«ãåœéçãªäººã ã«ç åäœãæã¡èŸŒãæ©äŒãæ¢ããŠãããšããããããã¯ãŸãã«ãã¯ã¿ãŒïŒã¡ã³ã°ã«...ïŒã®åœä»€ãšèšããããç¥ããªãã
ãã«ãã¬ã«ã§ã¯ããã«è€æ°ã®çäŸãçºèŠãããINSAãã«ãã¬ã«ã¯ããã®éå£çºçã«é¢é£ãããµã«çã®å€ç°äœã®ç³»çµ±å³ãäœæããããã«å¿ èŠãªãã£ãŒãã·ãŒã±ã³ã¹ãè¿ éã«å®æœããããšã¯ã倧ããªå瞟ã§ããã
ãã®çµæãçŸåšæµè¡ããŠãããµã«ã¢ããïŒè¥¿ã¢ããªã«ã®ã¯ã¬ãŒãïŒã®èµ·æºã«é¢ããé©ãã¹ã仮説ãšããã®ããŒã¿ãè¿ éã«å ¬éããŸãããæ¬é¡ã«å ¥ãã圌ãã®ããŒã¿ãšè«æãæ€èšããçµæããã®ç¹æ®ãªãŠã€ã«ã¹ã®èµ·æºã«é¢ããå€ãã®ãäœæ¥ä»®èª¬ãã®äžã€ã¯ããã®ãŠã€ã«ã¹ãå®éšå®€ããŒã¹ã®æäœã®ç£ç©ã§ããããŸãã«ä»¥åã®ã¢ãã«éãã§ãããšçµè«ã¥ããããåŸãªããªã£ãã®ã§ãããå®è©±ã§ãããçå®ã¯å°èª¬ãããå¥ãªããã§ããã
èè ã¯ããã®ç ç©¶ã®ç®çãšæ¹æ³ã次ã®ããã«ç°¡æœã«ïŒãã€ãšã¬ã¬ã³ãã«ïŒãŸãšããŠããã
ïŒè€æ°åœã§çºçããçãã®ãããµã«ããã¯ã¹ãŠã€ã«ã¹ã«é¢é£ããæåã®ãã©ããã²ãã é åã2022幎5æ (ãã«ãã¬ã«ã§ç¢ºèªãããäºäŸïŒ 184)ã«ç¶ããä»åãè€æ°åœã§ã®ã¢ãŠããã¬ã€ã¯ãèµ·ããããµã«çãŠã€ã«ã¹ã®ã²ãã é å9ä»¶ã远å å ¬éããããŸãããããã®é åã¯ã2022幎5æ15æ¥ããã³17æ¥ã«9äººã®æ£è ããæ¡åããèšåºæ€äœãããã€ã«ããæè¡ãçšãããã€ã¹ã«ãŒãããã®ã·ã§ããã¬ã³ã»ã¡ã¿ã²ããã¯ã¹ïŒè©³çްã¯äžèšåç §ïŒã«ããåŸããããã®ã§ããµã«ããã¯ã¹ã²ãã å šäœã®ã«ããŒæ·±åºŠã¯38xãã508xïŒå¹³å201xïŒã§ãã
æ°ãã«é åæ±ºå®ãããã²ãã ã¯ãUSA*ãå ¬éããé åãå«ãããµã«ããã¯ã¹ã®éºäŒç倿§æ§ã«æ¥éã«çµ±åãããã
Gigante et al, ãµã«ããã¯ã¹ãŠã€ã«ã¹å颿 ª MPXV_USA_2022_MA001, å®å šã²ãã - Nucleotide - NCBI 156
ãã®ããã§ã次ã®ãããªäž»ãªææãããŠããã
ãã®è€æ°åœã§çºçãããŠã€ã«ã¹ã¯åäžã®èµ·æºã§ããå¯èœæ§ãé«ãããããŸã§ã«çºè¡šããããã¹ãŠã®é åæ±ºå®æžã¿ãŠã€ã«ã¹*ãç·å¯ã«ã¯ã©ã¹ã¿ãªã³ã°ãããŠããŸãïŒå³1ïŒã
æåã®ãã©ããé åIsidroãã183ã«ãã£ãŠæããã«ããã系統é 眮ã®ç¢ºèªïŒã¢ãŠããã¬ã€ã¯ãŠã€ã«ã¹ã¯è¥¿ã¢ããªã«ã¯ã¬ãŒãã«å±ãã2018幎ãš2019幎ã«ãã€ãžã§ãªã¢ããè€æ°ã®åœãããªãã¡è±åœãã€ã¹ã©ãšã«ãã·ã³ã¬ããŒã«ãžã®ãµã«çãŠã€ã«ã¹ã®èŒžåºã«é¢é£ãããŠã€ã«ã¹ïŒå©çšå¯èœãªã²ãã ããŒã¿ã«åºã¥ãïŒã«æãè¿çžã§ãïŒ1ã2ïŒã
ããã§ããã¢ãŠããã¬ã€ã¯ãŠã€ã«ã¹ã¯ããããã®2018幎ãã2019幎ã®ãŠã€ã«ã¹ããå¹³å50SNPsïŒæãè¿ããªãã¡ã¬ã³ã¹MPXV_UK_P2ãMT903344.1ããã¯46SNPsïŒä¹é¢ããŠããïŒè¡š 1_2022-05-23.zipïŒ15.0 KBïŒïŒãããã¯ããªãŒãœããã¯ã¹ãŠã€ã«ã¹ã®æšå®çœ®æçïŒ3ïŒãèãããšäºæ³ãã¯ããã«è¶ ãããã®ã§ããã
Rambaut (Discussion of ongoing MPXV genome sequencing 228) ãè¿°ã¹ãŠããããã«ãAPOBEC3ç·šéã«ããé²åçãžã£ã³ãïŒè¶ å€ç°ãŠã€ã«ã¹ã«ã€ãªããïŒãåå²ã®åå ã§ãããšããä»®èª¬ãæšãŠãããªã(4)ã
æã ã¯ãã§ã«ãçºçã¯ã©ã¹ã¿ãŒå ã§ã®åŸ®å°é²åã®æåã®å åãããªãã¡7ã€ã®SNPïŒè¡š2_2022-05-23.zipïŒ10.9 KBïŒïŒã®åºçŸãæ€åºãã2ã€ã®é åïŒPT0005ãšPT0008ïŒãå«ããããªããµãã¯ã©ã¹ã¿ãŒïŒ2ã€ã®SNPã§ãµããŒãïŒãå«ã3ã€ã®åå«åå²ïŒå³1ïŒãå°ããŠãããæ³šç®ãã¹ãã¯ãããã2ã€ã®é åã¯ãAnkyrin/Host Range (Bang-D8L); D7Lã¿ã³ãã¯è³ªãã³ãŒãããMPXV-UK_P2-010éºäŒåã®913bpãã¬ãŒã ã·ããæ¬ 倱ãå ±æããŠããããšã§ããïŒMT903344.1ã¢ãããŒã·ã§ã³ïŒãéºäŒåæ¬ æçŸè±¡ã¯ãäžå€®ã¢ããªã«ã«ããããµã«çã®é¢šåç ã®æèã§æ¢ã«èгå¯ãããŠããããããããããžã®ææãšçžé¢ããŠãããšã®ä»®èª¬ããã(5)ã
ã§ããããåŠè¡çãªç§åŠã®è©±ã«ç²ŸéããŠããªã人ã¯ããã®æç¹ã§éŠããããããããã "ãªãããã®æå³ãããããããæããŠãããªãã®ãïŒ"ãšããå 容ã®ã³ã¡ã³ããæçš¿ããæºåãããŠããããšã§ãããã
ããã§ãåçŽåããããèŠæã§ïŒ
ãµã«çã®çºçã¯ãåäžã®ãªãªãžãã«ãªãŠã€ã«ã¹æºããçããŠããããã ãç§åŠçãªãçå®ãã«å°éããããã®ã仮説ãã¢ãã«ïŒããã¯ç§ãè¥ãç§åŠè ã ã£ãããã®æè²ã®äžæ žããªããŠããïŒã®æãã«åŸã£ãŠãaïŒããã¯ïŒäŸãã°ïŒããææåç©ããäžçã®ã©ããã§äžäººã®äººéïŒãããããã¹ãããã¹ã®ã²ã€ãã©ã€ãã®ã€ãã³ããšäœããã®é¢ä¿ããã£ãïŒã«ãèªç¶ã«ãèµ·ãã£ãã·ã³ã°ã«ãžã£ã³ãçŸè±¡ã§ããå¯èœæ§ãããããããã¯ãbïŒæå³çã«åé¢ããããŠã€ã«ã¹ãæŸåºãããå¯èœæ§ããããè¯ãããšãæªãããšãããè€éãªãã¥ãŒã¹
èè ãã¯ããã®æ°ããéå£çºçãŠã€ã«ã¹ããïŒç æ°ãåŒãèµ·ããã«ããïŒè¥¿ã¢ããªã«ã®ãµã«ããã¯ã¹ãŠã€ã«ã¹ã®ã°ã«ãŒãïŒã¯ã¬ãŒãïŒãã«ãããã³ã°ãããããšã確èªãããè¯ããã¥ãŒã¹
ãã®åäžçºçæºã®ãŠã€ã«ã¹ã¯ã西ã¢ããªã«ããæ¥ãå¯èœæ§ãããããã€ã®ãªã¹ãã€ã¹ã©ãšã«ãã·ã³ã¬ããŒã«ããæ¥ãå¯èœæ§ãããïŒä»®èª¬aãŸãã¯bã®ãããããšäžèŽããïŒãè¯ãããšãæªãããšãããè€éãªãã¥ãŒã¹
é åãããã®ãŠã€ã«ã¹ã2018ïœ2019幎ã«åé¢ããããã®ãšæãè¿çžã§ããããšã瀺ããŠããã«ãããããããèããç°ãªã£ãŠãããããã¯ãèªç¶é²åã«ãããã®ããå®éšå®€ã§ã®å·¥åŠïŒæ©èœç²åŸãç ç©¶ãã«ãããã®ãããããªãïŒä»®èª¬aïŒããã³bãšäžèŽããïŒãæŠããŠæªããã¥ãŒã¹ã ãåºæ¬çã«ãèè ãã¯ããã®ãŠã€ã«ã¹ã®ã²ãã ã¯ãäºæ¬éDNAããã¯ã¹ãŠã€ã«ã¹ããäºæ³ããããããæ¥éã«é²åããŠããããïŒèšãããããªããããã¯èª°ãããããããŸãããŠããïŒããšèããŠããããšã衚ããŠããã
èè ãã¯ããã®çªç¶å€ç°ã®ãã¿ãŒã³ã¯ãAPOBEC3ãšããç¥ç§°ã§åŒã°ãã倩ç¶ã®çŽ°èæ§ã¿ã³ãã¯è³ªã®åœ±é¿ãšäžèŽãããšæšæž¬ããŠãããAPOBEC3ã®ååãŠã€ã«ã¹åŠã«ã€ããŠè©³ããç¥ãããæ¹ã¯ã2015幎ã®J Immunologyèªã«æ²èŒãããã¬ãã¥ãŒãã芧ãã ãããã¯ãªãããŒãïŒèŠçŽçïŒããæ±ãã®æ¹ã¯ããŠã£ãããã£ã¢ãã芧ãã ãããAPOBEC3ã¯ãç¹å®ã®å¡©åºå€åãã¿ãŒã³ïŒCâUïŒãšé¢é£ããŠããããšã«æ³šæããŠãã ãããAPOBEC3ã®æœåšçãªåœ¹å²ã«é¢ãã圌ãã®ä»®èª¬ã«åºã¥ããèè ãã¯2018-2019幎ã®å颿 ªãšæ¯èŒããŠãçŸåšã®å颿 ªã§çµ±èšçã«ææãªå²åã®CâUå€åãæ€åºããã«éããªããšæšæž¬ããŠããŸããããã¯ã¹ãã¥ãŒã¹ - è¯ããããããªãããæªããããããªãããŸã 仮説a)ãŸãã¯ä»®èª¬b)ãåºå¥ããŠããªãã
ããã«åé¡ããããAPOBEC3ã¯HIVïŒããã³ããããä»ã®ã¬ãããŠã€ã«ã¹ïŒã«å¯ŸããçŽ°èæµææ§ïŒãèªç¶å ç«ãã®ããã«å¥ã®åœ¢æ -ååãŠã€ã«ã¹åŠãšçްèçç©åŠã¯çŽ æŽãããã§ã¯ãããŸãããïŒïŒãšé¢é£ããŠããŸãããPubMedæ€çŽ¢ã§ãããã¯ã¹ãŠã€ã«ã¹ã¯APOBC3ã®å€ç°å¹æã«æµææ§ãããããšãæããã«ãªããŸããïŒããã¯ãAPOBC3ã®å€ç°ã®åœ±é¿ãåããŠããããšã瀺ããŸããäŸãã°ããVirologyãèªã«æ²èŒããã2006幎ã®è«æãèŠãŠã¿ãããççŽã«èšã£ãŠã奜å¥å¿ã®æ¬ åŠãªã®ãããããšãæ¿åºã«æ¯é ãããã¡ãã£ã¢ãéèªããã®æ»æãæããŠããã®ããèè ããã®Virologyã®è«æã«ããèšåããªãã£ãã®ã¯ãããèšã£ãŠã倧ããªé倱ã§ãããšèšããã§ããããç§ã®æšè«ãšè§£éã¯ïŒäžèšã®INSAããŒã ããã®é ååæå ±åã«åºã¥ããŠãç§ã«ã¯ãããã¯èªç¶ã«é²åããæ ªãšããããããå®éšå®€ã§æäœãããæ ªã®ããã«èŠãããæªããã¥ãŒã¹ã ã
ããã«ããã®äºæ¬éDNAãŠã€ã«ã¹ã«ããææã¯æŽå²çã«èªå·±éå®çã§ãã£ãããïŒããæ°æ¥ã®éã«ïŒïŒãããããããžãã容æã«ææãã圢æ ã«é²åããŠããããã§ãããæªããã¥ãŒã¹ã ã
çµè«ãšããŠãçŸåšã®èšŒæ ã®åªäœæ§ã¯ããã®ã¢ãŠããã¬ã€ã¯ã®èµ·æºã«é¢ãã仮説ãæã瀺ããããã¯ã以åã®ãæŠäºã²ãŒã ãã®ã·ããªãªèšç»ãšãŸããŸãäžèŽããŠãããã€ãã³ã201ã§èµ·ãã£ãããšã«èãã䌌ãŠããã2022幎ã®5æäžæ¬ã«äººå·¥ã®ç¿çãŠã€ã«ã¹ã人éã®éå£ã«åºçŸãããšä»®å®ããŠããŸãã
ããªãèªèº«ã®çµè«ãåºããããªãèªèº«ã®ç ç©¶ãããŠäžããã